{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:47:32Z","timestamp":1776185252689,"version":"3.50.1"},"reference-count":124,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.iac.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:20:49Z","timestamp":1599931249000},"page":"667-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting Mast Cells with Biologics"],"prefix":"10.1016","volume":"40","author":[{"given":"Jonathan J.","family":"Lyons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaci.2018.01.034","article-title":"Mast cells signal their importance in health and disease","volume":"142","author":"Olivera","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2020.06.007_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"6760 Suppl","key":"10.1016\/j.iac.2020.06.007_bib4","doi-asserted-by":"crossref","first-page":"B24","DOI":"10.1038\/35037021","article-title":"Signalling through the high-affinity IgE receptor Fc epsilonRI","volume":"402","author":"Turner","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/imr.12625","article-title":"Changing the threshold-signals and mechanisms of mast cell priming","volume":"282","author":"Halova","year":"2018","journal-title":"Immunol Rev"},{"issue":"1\u20133","key":"10.1016\/j.iac.2020.06.007_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12026-008-8046-9","article-title":"Amplification mechanisms for the enhancement of antigen-mediated mast cell activation","volume":"43","author":"Gilfillan","year":"2009","journal-title":"Immunol Res"},{"issue":"5","key":"10.1016\/j.iac.2020.06.007_bib7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.iac.2020.06.007_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/107999004323065057","article-title":"The role of human mast cell-derived cytokines in eosinophil biology","volume":"24","author":"Shakoory","year":"2004","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.iac.2020.06.007_bib11","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib12","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2796.1993.tb00984.x","article-title":"Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis","volume":"233","author":"Kors","year":"1993","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0b013e32833b280c","article-title":"Mastocytosis and insect venom allergy","volume":"10","author":"Bonadonna","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1258\/jrsm.2008.070306","article-title":"Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England","volume":"101","author":"Sheikh","year":"2008","journal-title":"J\u00a0R Soc Med"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib20","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.anai.2019.08.024","article-title":"Idiopathic anaphylaxis yardstick: practical recommendations for clinical practice","volume":"124","author":"Carter","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"10.1016\/j.iac.2020.06.007_bib22","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.007_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clinthera.2013.04.001","article-title":"Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes","volume":"35","author":"Picard","year":"2013","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.iac.2013.09.012","article-title":"Chronic spontaneous urticaria: etiology and pathogenesis","volume":"34","author":"Saini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib28","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1102140","article-title":"Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions","volume":"366","author":"Ombrello","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2020.06.007_bib30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMoa1500611","article-title":"Vibratory urticaria associated with a missense variant in ADGRE2","volume":"374","author":"Boyden","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.iac.2020.06.007_bib31","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"10","key":"10.1016\/j.iac.2020.06.007_bib33","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human alpha\/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.iac.2020.06.007_bib34","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","author":"Lyons","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.007_bib35","series-title":"Zur Theorie und Praxis der histologischen F\u00e4rbung","author":"Beitr\u00e4ge","year":"1878"},{"issue":"4580","key":"10.1016\/j.iac.2020.06.007_bib36","first-page":"2","article-title":"Innoculation against hay fever","volume":"177","author":"Prophylactic","year":"1911","journal-title":"Lancet"},{"issue":"4594","key":"10.1016\/j.iac.2020.06.007_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(01)40417-X","article-title":"Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine","volume":"178","author":"Freeman","year":"1911","journal-title":"Lancet"},{"issue":"6821","key":"10.1016\/j.iac.2020.06.007_bib38","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(54)91620-7","article-title":"Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component","volume":"266","author":"Frankland","year":"1954","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3181\/00379727-64-15727","article-title":"Liberation of histamine and heparin by peptone from the isolated dog's liver","volume":"64","author":"Rocha e Silva","year":"1947","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib40","first-page":"72P","article-title":"Histamine in tissue mast cells","volume":"117","author":"Riley","year":"1952","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.iac.2020.06.007_bib41","first-page":"160","article-title":"Studien \u00fcber die \u00dcberempfindlichkeit","volume":"86","author":"Prausnitz","year":"1921","journal-title":"Centralbl Bakterio"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4049\/jimmunol.99.6.1187","article-title":"Identification of gamma-E-antibodies as a carrier of reaginic activity","volume":"99","author":"Ishizaka","year":"1967","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.anai.2018.07.014","article-title":"New approaches to allergen immunotherapy","volume":"121","author":"Gunawardana","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaci.2016.01.001","article-title":"Food allergen immunotherapy: current status and prospects for the future","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2005.01.005","article-title":"Insect sting allergy and venom immunotherapy: a model and a mystery","volume":"115","author":"Golden","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40413-015-0063-2","article-title":"Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens","volume":"8","author":"Akdis","year":"2015","journal-title":"World Allergy Organ J"},{"issue":"5","key":"10.1016\/j.iac.2020.06.007_bib47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib48","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaip.2017.11.025","article-title":"Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected","volume":"6","author":"Bonadonna","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1 Pt 1","key":"10.1016\/j.iac.2020.06.007_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0091-6749(97)81058-5","article-title":"Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis","volume":"99","author":"Oude Elberink","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.007_bib50","doi-asserted-by":"crossref","first-page":"11610","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"issue":"8 Pt 2","key":"10.1016\/j.iac.2020.06.007_bib51","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","article-title":"Anti-immunoglobulin E (omalizumab) therapy in allergic asthma","volume":"164","author":"Busse","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib52","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.4049\/jimmunol.179.2.1353","article-title":"Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells","volume":"179","author":"Gomez","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fce psilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2020.06.007_bib54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iac.2020.06.007_bib55","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstrom","year":"2019","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib56","doi-asserted-by":"crossref","first-page":"17453","DOI":"10.1038\/s41598-017-16730-6","article-title":"Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial","volume":"7","author":"Takahashi","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaip.2018.09.015","article-title":"Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab","volume":"7","author":"Yee","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib58","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.iac.2020.06.007_bib59","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2019.09.026","article-title":"Clinical response to omalizumab in patients with hereditary alpha-tryptasemia","volume":"124","author":"Mendoza Alvarez","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"14","key":"10.1016\/j.iac.2020.06.007_bib61","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib63","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2500\/108854107781285717","article-title":"The unusual suspects: a surprise regarding reactions to omalizumab","volume":"28","author":"Lieberman","year":"2007","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib65","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.anai.2018.02.018","article-title":"Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate","volume":"120","author":"Perino","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib66","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib67","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41467-018-03636-8","article-title":"Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement","volume":"9","author":"Orengo","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib68","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1084\/jem.183.6.2681","article-title":"Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in\u00a0vivo","volume":"183","author":"Costa","year":"1996","journal-title":"J\u00a0Exp Med"},{"issue":"9","key":"10.1016\/j.iac.2020.06.007_bib69","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood.V89.9.3136","article-title":"Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I\/II trial","volume":"89","author":"Moskowitz","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib70","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","article-title":"Stem cell factor and hematopoiesis","volume":"90","author":"Broudy","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib71","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.iac.2018.04.007","article-title":"Tyrosine kinase inhibition in mastocytosis: KIT and beyond KIT","volume":"38","author":"Bibi","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"10","key":"10.1016\/j.iac.2020.06.007_bib72","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-16-2152","article-title":"KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells","volume":"23","author":"London","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib73","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2017.02.011","article-title":"Decoupling the functional pleiotropy of stem cell factor by tuning c-Kit signaling","volume":"168","author":"Ho","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.iac.2020.06.007_bib74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"6 Pt 1","key":"10.1016\/j.iac.2020.06.007_bib75","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1067\/mai.2000.107127","article-title":"Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils","volume":"105","author":"Kikly","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib76","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.iac.2020.06.007_bib77","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1182\/blood-2002-10-3058","article-title":"Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis","volume":"101","author":"Nutku","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib78","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaci.2007.10.004","article-title":"Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement","volume":"121","author":"Yokoi","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.iac.2020.06.007_bib79","doi-asserted-by":"crossref","first-page":"e126219","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cyto.2015.01.038","article-title":"History of interleukin-4","volume":"75","author":"Paul","year":"2015","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib81","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.0901860","article-title":"IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation","volume":"184","author":"Sehra","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib82","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.4049\/jimmunol.166.4.2712","article-title":"IL-13 overexpression predisposes to anaphylaxis following antigen sensitization","volume":"166","author":"Fallon","year":"2001","journal-title":"J\u00a0Immunol"},{"issue":"6456","key":"10.1016\/j.iac.2020.06.007_bib83","doi-asserted-by":"crossref","first-page":"eaaw6433","DOI":"10.1126\/science.aaw6433","article-title":"Identification of a T follicular helper cell subset that drives anaphylactic IgE","volume":"365","author":"Gowthaman","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib84","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/mi.2012.112","article-title":"Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy","volume":"6","author":"Burton","year":"2013","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cyto.2015.05.019","article-title":"Mast cell production and response to IL-4 and IL-13","volume":"75","author":"McLeod","year":"2015","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib86","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0091-6749(98)70140-X","article-title":"Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells","volume":"102","author":"Toru","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2020.06.007_bib87","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1398-9995.2012.02859.x","article-title":"Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice","volume":"67","author":"Komai-Koma","year":"2012","journal-title":"Allergy"},{"issue":"10209","key":"10.1016\/j.iac.2020.06.007_bib88","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.iac.2020.06.007_bib89","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.iac.2020.06.007_bib90","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib91","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jaci.2015.09.059","article-title":"IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3","volume":"137","author":"Desai","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib92","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","article-title":"IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis","volume":"115","author":"Brockow","year":"2005","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib93","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib94","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib95","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.2018.212126","article-title":"Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production","volume":"105","author":"Tobio","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.iac.2020.06.007_bib96","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.182.1.647","article-title":"Mast cells contribute to autoimmune inflammatory arthritis via their tryptase\/heparin complexes","volume":"182","author":"Shin","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib97","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.4049\/jimmunol.1003049","article-title":"A\u00a0brief history of IL-9","volume":"186","author":"Goswami","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib98","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/eji.1830200632","article-title":"Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T\u00a0cell growth factor P40\/TCGFIII (interleukin 9)","volume":"20","author":"Hultner","year":"1990","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib99","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2015.01.021","article-title":"TH9 cells are required for tissue mast cell accumulation during allergic inflammation","volume":"136","author":"Sehra","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.007_bib100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-14-93","article-title":"A\u00a0randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma","volume":"14","author":"Oh","year":"2013","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.iac.2020.06.007_bib101","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"515","key":"10.1016\/j.iac.2020.06.007_bib102","doi-asserted-by":"crossref","first-page":"eaax2945","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"22","key":"10.1016\/j.iac.2020.06.007_bib103","doi-asserted-by":"crossref","first-page":"e131347","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib104","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaci.2016.09.049","article-title":"IL-33 fine tunes mast cell degranulation and chemokine production at the single-cell level","volume":"140","author":"Joulia","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/cells8040341","article-title":"IL-33 and MRGPRX2-triggered activation of human skin mast cells-elimination of receptor expression on chronic exposure, but reinforced degranulation on acute priming","volume":"8","author":"Wang","year":"2019","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.iac.2020.06.007_bib106","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.179.9.6072","article-title":"Mast cell alpha and beta tryptases changed rapidly during primate speciation and evolved from gamma-like transmembrane peptidases in ancestral vertebrates","volume":"179","author":"Trivedi","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib107","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2006.02.026","article-title":"Tryptase genetics and anaphylaxis","volume":"117","author":"Caughey","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"22","key":"10.1016\/j.iac.2020.06.007_bib108","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.1016\/S0021-9258(19)68496-6","article-title":"Tryptase from human pulmonary mast cells. Purification and characterization","volume":"256","author":"Schwartz","year":"1981","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib109","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2019.09.009","article-title":"An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma","volume":"179","author":"Maun","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.iac.2020.06.007_bib110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib111","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1084\/jem.20182015","article-title":"A\u00a0novel human IL2RB mutation results in T and NK cell-driven immune dysregulation","volume":"216","author":"Fernandez","year":"2019","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib112","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1172\/JCI117765","article-title":"Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency","volume":"95","author":"Schmalstieg","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.iac.2020.06.007_bib113","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1073\/pnas.94.7.3168","article-title":"Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor","volume":"94","author":"Sharfe","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.iac.2020.06.007_bib114","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1084\/jem.20182304","article-title":"Human interleukin-2 receptor beta mutations associated with defects in immunity and peripheral tolerance","volume":"216","author":"Zhang","year":"2019","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"10.1016\/j.iac.2020.06.007_bib115","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib116","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s13311-017-0553-8","article-title":"Daclizumab: development, clinical trials, and practical aspects of use in multiple sclerosis","volume":"14","author":"Baldassari","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.iac.2020.06.007_bib117","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3109\/10428190903470869","article-title":"Treatment of aggressive systemic mastocytosis with daclizumab","volume":"51","author":"Quintas-Cardama","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"10125","key":"10.1016\/j.iac.2020.06.007_bib118","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(18)30565-8","article-title":"End of the road for daclizumab in multiple sclerosis","volume":"391","author":"The","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iac.2020.06.007_bib119","first-page":"175","article-title":"The role of basiliximab in the evolving renal transplantation immunosuppression protocol","volume":"2","author":"Salis","year":"2008","journal-title":"Biologics"},{"issue":"9","key":"10.1016\/j.iac.2020.06.007_bib120","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.iac.2020.06.007_bib121","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.2147\/OTT.S141053","article-title":"Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review","volume":"11","author":"Donato","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.iac.2020.06.007_bib122","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","article-title":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","volume":"44","author":"Borate","year":"2016","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.iac.2020.06.007_bib123","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.iac.2020.06.007_bib124","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/leu.2016.30","article-title":"Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia","volume":"30","author":"Alvarez-Twose","year":"2016","journal-title":"Leukemia"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:43:46Z","timestamp":1760179426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856120300424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0889856120300424"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.007","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Mast Cells with Biologics","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}